key: cord-0910764-7zbl391x
authors: Rostami Mansoor, Sahar; Ghasemi‐Kasman, Maryam
title: Impact of disease‐modifying drugs on the severity of COVID‐19 infection in multiple sclerosis patients
date: 2020-10-30
journal: J Med Virol
DOI: 10.1002/jmv.26593
sha: 63f584a1569e451aae609db5ccbb4e5cd306b528
doc_id: 910764
cord_uid: 7zbl391x

Recent evidence suggested that neurological manifestations occur in patients with a severe form of coronavirus disease (COVID‐19). On the basis of this issue, neurologists are very concerned about patients with neurological disorders, especially multiple sclerosis (MS), as consumers of immunosuppressive or immune‐modulating drugs. Therefore, the administration of proper disease‐modifying therapies (DMTs) in MS patients is critical during the pandemic status. On the one hand, both the autoimmune diseases and immunosuppressive drugs increase the risk of infection due to impairment in the immune system, and on the other hand, postponing of MS treatment has serious consequences on the central nervous system. In the present study, we discussed recent literature about the effect of DMTs administration on the severity of COVID‐19 in the MS patients. Overall, it seems that DMTs do not provoke the COVID‐19 infection in the MS patients by declining immune responses and cytokine storm. However, as a precaution, the supervision of a neurologist is highly recommended.

genomic sequencing showed the presence of SARS-CoV-2 in the cerebrospinal fluid of patients. 11 Therefore, any pathogenicity that impairs the integrity of the blood-brain barrier may increase the neurological involvement in COVID-19 patients.

To increase the survival of COVID-19 patients with concomitant neurological diseases, especially MS patients, neurologists are looking for effective therapies. Theoretically, MS patients as consumers of immunosuppressive or immune-modulating drugs are at a higher risk for COVID-19. 12 Therefore, the selection of a proper drug to start or continue MS therapies is very important for reducing mortality and morbidity in the MS patients with COVID-19.

In the present review article, we aim to discuss recent reports about the effect of various disease-modifying therapies (DMTs) on the severity of COVID-19 or even prevention of its progression in MS patients.

The immune responses against coronavirus include innate and adaptive immunities. The innate immunity is the first response in the circulatory system and peripheral tissue, especially lung alveolar. 13 Lymphopenia and cytokine storm are the major hallmarks of patients with a severe form of COVID-19. Recently, a lower level of T-helper (Th) cells, dysregulation between Th1 and Th2, and an increased level of naïve Th cells have been reported in COVID-19 patients. In addition to lymphocytes, higher levels of B cells, innate immune cells, and inflammatory cytokines have also been found in severe cases of COVID-19. 14, 15 In this regard, the levels of antinucleocapsid and antispike protein antibodies were enhanced in the circulatory system of COVID-19 cases. A previous report has indicated that the risk of COVID-19 infection increases in individuals with X-linked agammaglobulinemia. This evidence indicates that B-cell activity is not indispensable for protection against SARS-CoV-2 infection. 16 A recent study on 99 patients with COVID-19 showed the elevation of neutrophils (38%), IL-6 (52%), and C-reactive protein (CRP; 84%) versus reduced total lymphocytes (35%). 15 Other cytokines such as IL-10, IL-2R, and TNF-α have also been observed to be drastically elevated in the severe form of COVID-19. 17 

Both autoimmune diseases and immunosuppressive drugs increase the risk of infection due to impairment in the immune system. Although the use of immunosuppressive drugs was a major leap in the control of MS progression, but due to the nature of these drugs, MS patients are at a higher risk of bacterial, fungal, parasitic, and viral infections. Studies revealed that immunosuppressive drugs increase the risk of hepatitis B virus, hepatitis C virus, cytomegalovirus, and herpes virus by leukocytosis, lymphopenia, lymphoid redistribution, and diminishing immune surveillance in the CNS. 18 Therefore, the inflammatory status of patients before drug administration, during consumption, and at the end of treatment should be precisely monitored. 18 It should be also noted that other factors such as older age, sex, worse physical disability, and lower concomitant status increase the risk of infection and hospitalization in MS patients. 18, 19 In the current situation where COVID-19 has rapidly spread around the world, it could theoretically be admitted that MS patients are at a higher risk of infection and health anxiety. 20 Furthermore, during the COVID-19 crisis, the access of MS patients to their therapist teams, psychologists, and physiotherapists is restricted, which exacerbates the severity of the disease. To reduce the mental and physical impairments in MS patients, it has been suggested that regular exercise, yoga, and other therapeutic options such as online support are very helpful during the pandemic condition. However, the lack of pragmatic methods raises the concern of neurologists about severe infections in the MS patients. 20 

We have performed a PubMed search to find articles, which have Fingolimod (FTY720) as an agonist of sphingosine-1-phosphate (S1P) receptor internalizes S1P and leads to the redistribution of lymphocytes, thus reducing their entry into the CNS. 21 It has not been reported that FTY720 increases the infectionary rate in participants enrolled in the initial multisite randomized phase 3 controlled trials, 22 but post-marketing surveillance suggested that long-term consumption of FTY720 may increase the risk of several infections. 23 Foerch et al. reported a 58-year-old female relapsing-remitting multiple sclerosis (RRMS) patient with severe COVID-19 infection under FTY720 treatment. Five days after stopping FTY720 and performing the necessary medical care in the intensive care unit (ICU), the patient was transferred to a normal ward. It has been suggested that FTY720 has complex effects on COVID-19 through S1P receptor. It has been shown that S1P receptor is an angiogenic factor that improves endothelial integrity, vascular permeability, and alveolar flooding. Furthermore, FTY720 as an immunosuppressive agent prevents cytokine storm by reducing naïve T cells and memory T cells. Hence, it might be considered as an effective therapy for reducing the mortality rate of COVID-19 cases. 24 Barzegar and colleagues reported a 61-year-old female RRMS patient under FTY720 therapy. The patient was transferred to the hospital after the symptoms of relapse or pseudoexacerbation and clinical and paraclinical findings of COVID-19. Clinicians speculated that the nCoV was likely to cause pseudoexacerbation or relapse without a clear etiology in the MS case. Despite multiple comorbidities in this patient, the COVID-19 infection was resolved with a favorable outcome. 25 It seems that MS and FTY720 consumption did not complicate the treatment procedure in COVID-19 patients.

Furthermore, previous studies revealed that discontinuation of immunotherapies such as FTY720 leads to rebound MS disease activity. 26 Therefore, FTY720 cessation may initiate severe relapse in MS patients with COVID-19.

with RRMS who was hospitalized in the ICU due to acute respiratory distress syndrome (ARDS). FTY720 as a main used drug in the last 4 years was stopped and one dose of tocilizumab was administered intravenously. As a result, the levels of IL-6, CRP, ferritin, D-dimer, and lactate dehydrogenase were dramatically enhanced in the patient. After more than 6 days, all the markers were reduced and there was an improvement in the infection. It has been suggested that tion. Therefore, it has been suggested that cladribine could be considered as a proper drug in terms of COVID-19 vaccination. 42 However, the conclusion of this issue may be reversed if addressed from another perspective. As mentioned above, the severity of COVID-19 is associated with the immune response to SARS-CoV-2. The invasion of inflammatory cytokines in systemic circulation causes damage to several tissues, especially lung. IL-6 is regarded as one of the principal cytokines that triggers the inflammatory cascade and leads to worse outcomes in COVID-19 patients. 43 Furthermore, IL-6 is involved in the pathogenicity of MS by stimulating T cells to produce IL-17. 44 It has even been reported that rheumatoid arthritis progressed to MS under repeated tocilizumab treatment. 45 They suggested that ARDS that occurs in a severe form of COVID-19 is an immune-mediated response. Therefore, reduced severe immune reactions against the virus could alleviate the mortality rate in MS patients under immunosuppressive treatment. 12 On the basis of this evidence, several routine drugs for MS patients are being evaluated to reduce the severity of COVID-19.

There are several drugs for MS treatment to prevent relapses and disability progression. 46 The mechanisms of these drugs are IFN-β and glatiramer acetate are immune modulator drugs without any immunosuppressive effects. Therefore, these therapies are considered as safe drugs to start or continue treatment in MS patients. It has been shown that first-generation drugs do not interfere with response to the seasonal influenza vaccine. 51 Therefore, it seems promising that their administration will be unrestricted after the production of the SARS-CoV-2 vaccine. Natalizimab has been introduced as an antagonist of α4 subunit of the cell adhesion molecule. It has been reported that "very late antigen 4" (VLA-4) has a partial effect on the suppression of the immune system. 46 However, it has been shown that natalizimab is a proper drug to start MS treatment in pandemic status, but previous studies have reported a higher risk of respiratory infection in natalizimab-receiving patients. 47, 52, 53 It has been postulated that reduced traffic of lymphocytes in the lungs and mucosa may increase the risk of respiratory infection. The treatment interval for natalizumab in MS patients is 4 weeks, but some studies revealed that no changes occur in MS patient's stability by extending the interval dosage to 8 weeks. Therefore, it has been recommended that the treatment interval for natalizumab should be 6 weeks in the pandemic situation. 28, 51 Similarly, the interval between rituximab dosages could be increased from 6 months to 9-12 months. 51 Rituximab and ocrelizumab as moderate immunosuppressive drugs have a remarkable effect on B-cell depletion. 4, 54 In this regard, Safavi et al. reported that B cell-depleting antibodies increase the incidence of COVID-19 infection in MS patients. However, this infection was mild to moderate and there was no correlation between B cell-depleting antibodies and hospitalization. 55 In another study, Sahraian et al. 48 showed that rituximab enhances the rate of COVID-19 infection in the MS patients without any effect on the hospitalization rate. However, Crescenzo et al. 56 observed no correlation between specific DMT and a higher risk of COVID-19 in the MS patients. Furthermore, it should be noted that rituximab may impair the response to SARS-CoV-2 vaccine, as it has previously impaired the effect of seasonal influenza vaccine. 57, 58 The highest risk of infection is due to the immune reconstitution therapies during the depletion phase of the treatment. 57 Cladribine, alemtuzumab, and hematopoietic stem cell transplantation (HSCT) are the most important therapeutic approaches in this category. The mentioned therapies lead to complete lymphocyte depletion and increase the risk of viral infection until the total lymphocyte count reaches over 1.1 × 10 9 /L, followed by which the infection rate may gradually decrease and reach the level of normal condition. 59 However, as mentioned above, MS patients under cladribine and alemtuzumab therapies show mild-to-moderate symptoms of COVID-19 infection.

SARS-CoV-2 is a pandemic infection and may take several years to subside. In addition, at best, vaccine production may take 12-18 months. Therefore, failure to use the appropriate dose of the immunosuppressive drugs or postponing treatment of MS patients may have serious consequences on the CNS as a precious tissue. Therefore, patient's follow-up and observance of hygienic principles are the most important strategies to alleviate the SARS-CoV-2 infection rate in the MS patients. Patient's follow-up is especially important in patients who have been treated by HSCT, alemtuzumab, and cladribin, or have other risk factors such as ambulatory status, old age, overweight, cancer, diabetes, and heart failure.

COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: "what the bleep do we know?

A novel coronavirus from patients with pneumonia in China

Neurology in the Time of COVID-19

Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Nervous system involvement after infection with COVID-19 and other coronaviruses

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Update on neurological manifestations of COVID-19

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

First case of 2019 novel coronavirus disease with encephalitis

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic

Clinical and immunologic features in severe and moderate forms of coronavirus disease

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: a new challenge

Disease-modifying therapies and infectious risks in multiple sclerosis

Dramatically changing rates and reasons for hospitalization in multiple sclerosis

Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients

Fingolimod and cryptococcosis: collision of immunomodulation with infectious disease

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

Fingolimod rebound: a review of the clinical experience and management considerations

A fine balance: immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19

COVID-19 occurring during natalizumab treatment: a case report in a patient with extended interval dosing approach

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role

Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: a mild uncomplicated infection despite intense immunosuppression

Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab

COVID-19 and multiple sclerosis: a description of two cases on alemtuzumab

COVID-19 in teriflunomide-treated patients with multiple sclerosis

Teriflunomide and its mechanism of action in multiple sclerosis

Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse

Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis

COVID-19 in dimethyl fumaratetreated patients with multiple sclerosis

IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis

Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate

COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice

Tocilizumab treatment in COVID-19: a single center experience

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

MS arising during tocilizumab therapy for rheumatoid arthritis

Multiple sclerosis: overview of disease-modifying agents

Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/ SARS-CoV-2

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis

COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center

Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients

Treatment of multiple sclerosis under the COVID-19 pandemic

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis

Ocrelizumab versus placebo in primary progressive multiple sclerosis

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

Frequency and severity of COVID-19 in multiple sclerosis: a short single-site report from northern Italy

The COVID-19 pandemic and the use of MS disease-modifying therapies

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis

Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study

Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients

The authors declare that there are no conflict of interests.

Kasman designed and supervised the study.

http://orcid.org/0000-0002-5014-5166